VIR Vir Biotechnology Inc

Price (delayed)

$39.09

Market cap

$5.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.36

Enterprise value

$4.43B

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are ...

Highlights
VIR's revenue has soared by 152% from the previous quarter and by 143% YoY
The company's gross profit has surged by 150% QoQ and by 142% YoY
VIR's quick ratio has surged by 141% since the previous quarter but it is down by 44% year-on-year
The net income has declined by 35% year-on-year but it has increased by 24% since the previous quarter
The debt has grown by 3.5% from the previous quarter

Key stats

What are the main financial stats of VIR
Market
Shares outstanding
130.61M
Market cap
$5.11B
Enterprise value
$4.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.89
Price to sales (P/S)
27.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.22
Earnings
Revenue
$182.71M
EBIT
-$297.12M
EBITDA
-$286.84M
Free cash flow
-$88.01M
Per share
EPS
-$2.36
Free cash flow per share
-$0.68
Book value per share
$5.67
Revenue per share
$1.4
TBVPS
$7.74
Balance sheet
Total assets
$1.06B
Total liabilities
$320.26M
Debt
$68.94M
Equity
$737.33M
Working capital
$716.27M
Liquidity
Debt to equity
0.09
Current ratio
5.91
Quick ratio
5.7
Net debt/EBITDA
2.37
Margins
EBITDA margin
-157%
Gross margin
99.4%
Net margin
-162.8%
Operating margin
-160.7%
Efficiency
Return on assets
-29.3%
Return on equity
-40.8%
Return on invested capital
-100%
Return on capital employed
-32.6%
Return on sales
-162.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
-2.83%
1 week
5.56%
1 month
-25.27%
1 year
-5.99%
YTD
45.97%
QTD
-10.18%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$182.71M
Gross profit
$181.56M
Operating income
-$293.64M
Net income
-$297.36M
Gross margin
99.4%
Net margin
-162.8%
VIR's revenue has soared by 152% from the previous quarter and by 143% YoY
The company's gross profit has surged by 150% QoQ and by 142% YoY
The net margin has soared by 70% from the previous quarter and by 45% YoY
The company's operating margin has surged by 70% QoQ and by 43% YoY

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
6.89
P/S
27.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.22
The EPS rose by 24% since the previous quarter
Vir Biotechnology's equity has increased by 31% YoY and by 13% from the previous quarter
VIR's price to book (P/B) is 3% lower than its last 4 quarters average of 7.1
VIR's revenue has soared by 152% from the previous quarter and by 143% YoY
The price to sales (P/S) is 50% lower than the last 4 quarters average of 55.7

Efficiency

How efficient is Vir Biotechnology business performance
The return on sales has surged by 70% since the previous quarter and by 45% year-on-year
Vir Biotechnology's return on equity has increased by 50% YoY and by 28% QoQ
Vir Biotechnology's return on assets has increased by 31% QoQ and by 31% YoY
The return on invested capital rose by 23% since the previous quarter but it has declined by 3% year-on-year

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
The company's total liabilities has surged by 195% YoY but it fell by 34% QoQ
VIR's quick ratio has surged by 141% since the previous quarter but it is down by 44% year-on-year
The debt is 91% less than the equity
Vir Biotechnology's equity has increased by 31% YoY and by 13% from the previous quarter
The debt to equity fell by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.